Investors

Recent Releases

March 3, 2026

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

GAITHERSBURG, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of John D. Fowler, Jr. to its board of directors effective March 1, 2026. Mr. Fowler brings more than three decades of leadership experience across the healthcare and

February 26, 2026

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 million Fourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37% Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior year Full Year 2025 Net Income

February 26, 2026

Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness

WINNIPEG, Manitoba, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced a series of new contracts and a contract modification with the Public Health Agency of Canada (PHAC) and the Department of National Defence (DND) to deliver critical medical countermeasures to